Orient Pharma Co., Ltd. (TPEX: 4166)
Taiwan
· Delayed Price · Currency is TWD 38.95
-0.45 (-1.14%)
Nov 21, 2024, 2:56 PM CST
Orient Pharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 1,066 | 889.91 | 511.86 | 463.34 | 412.01 | 353.54 | Upgrade
|
| Revenue Growth (YoY) | 65.47% | 73.86% | 10.47% | 12.46% | 16.54% | 31.16% | Upgrade
|
| Cost of Revenue | 480.45 | 421.25 | 356.51 | 320.67 | 336.86 | 339.85 | Upgrade
|
| Gross Profit | 585.21 | 468.67 | 155.35 | 142.67 | 75.15 | 13.69 | Upgrade
|
| Selling, General & Admin | 346.66 | 341.01 | 67.83 | 56.45 | 57.97 | 65.43 | Upgrade
|
| Research & Development | 83.87 | 99.9 | 129.25 | 219.72 | 183.94 | 153.62 | Upgrade
|
| Operating Expenses | 441.19 | 444.35 | 197.09 | 276.16 | 241.91 | 219.06 | Upgrade
|
| Operating Income | 144.02 | 24.32 | -41.74 | -133.49 | -166.75 | -205.37 | Upgrade
|
| Interest Expense | -14.3 | -13.9 | -7.37 | -5.7 | -5.38 | -4.93 | Upgrade
|
| Interest & Investment Income | 3.03 | 1.68 | 1.09 | 0.52 | 0.41 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 2.26 | 1.07 | 5.31 | 1.25 | 0.91 | -0.7 | Upgrade
|
| Other Non Operating Income (Expenses) | 16.33 | 9.79 | 1.72 | 37.33 | 5.17 | 8.58 | Upgrade
|
| EBT Excluding Unusual Items | 151.34 | 22.95 | -40.99 | -100.09 | -165.65 | -202.42 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.04 | -0.04 | -0.13 | - | - | - | Upgrade
|
| Asset Writedown | - | - | - | -10 | - | - | Upgrade
|
| Other Unusual Items | 0.01 | 0.01 | 0.01 | - | - | 0.01 | Upgrade
|
| Pretax Income | 151.31 | 22.92 | -41.11 | -110.09 | -165.65 | -202.41 | Upgrade
|
| Income Tax Expense | 32.21 | 0.64 | -12.35 | -7.44 | 5.73 | -1.39 | Upgrade
|
| Net Income | 119.1 | 22.29 | -28.76 | -102.65 | -171.38 | -201.03 | Upgrade
|
| Net Income to Common | 119.1 | 22.29 | -28.76 | -102.65 | -171.38 | -201.03 | Upgrade
|
| Shares Outstanding (Basic) | 223 | 223 | 187 | 187 | 169 | 156 | Upgrade
|
| Shares Outstanding (Diluted) | 223 | 223 | 187 | 187 | 169 | 156 | Upgrade
|
| Shares Change (YoY) | 8.79% | 19.27% | -0.00% | 10.40% | 8.57% | 0.15% | Upgrade
|
| EPS (Basic) | 0.53 | 0.10 | -0.15 | -0.55 | -1.01 | -1.29 | Upgrade
|
| EPS (Diluted) | 0.53 | 0.10 | -0.15 | -0.55 | -1.01 | -1.29 | Upgrade
|
| Free Cash Flow | 145.12 | -157.1 | -17.01 | -120.1 | -222.38 | -155.3 | Upgrade
|
| Free Cash Flow Per Share | 0.65 | -0.70 | -0.09 | -0.64 | -1.31 | -1.00 | Upgrade
|
| Gross Margin | 54.92% | 52.66% | 30.35% | 30.79% | 18.24% | 3.87% | Upgrade
|
| Operating Margin | 13.51% | 2.73% | -8.15% | -28.81% | -40.47% | -58.09% | Upgrade
|
| Profit Margin | 11.18% | 2.50% | -5.62% | -22.15% | -41.59% | -56.86% | Upgrade
|
| Free Cash Flow Margin | 13.62% | -17.65% | -3.32% | -25.92% | -53.97% | -43.93% | Upgrade
|
| EBITDA | 260.01 | 138.97 | 12.43 | -82.31 | -114.32 | -150.67 | Upgrade
|
| EBITDA Margin | 24.40% | 15.62% | 2.43% | -17.76% | -27.75% | -42.62% | Upgrade
|
| D&A For EBITDA | 115.99 | 114.65 | 54.17 | 51.18 | 52.43 | 54.69 | Upgrade
|
| EBIT | 144.02 | 24.32 | -41.74 | -133.49 | -166.75 | -205.37 | Upgrade
|
| EBIT Margin | 13.51% | 2.73% | -8.15% | -28.81% | -40.47% | -58.09% | Upgrade
|
| Effective Tax Rate | 21.29% | 2.77% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.